Use of Bevacizumab in Advanced Ovarian Cancer: Consensus from an Expert Panel Oncologists

Advani, Suresh H.; Doval, Dinesh Chandra; Koppikar, Smruti; Reddy, P. Vijay Anand; Prasad, Shiva; Bapna, Ajay; Parameswaran, Narayanan; Dwary, Amit Dutt; Krishna, Vidya; Dhanushkodi, Manikandan; Joel, Anjana; Pillai, Unni; K, G.Srinivas; Ramanjinappa, Nagendra

doi:10.1007/s40944-020-00485-6

Cited by 2 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar therapies are rarely available for OC. Previously, ANTHALYA and GEICO 1205/NOVA clinical trials provided evidence on bevacizumab as a NACT in addition to chemotherapy in advanced OC, suggesting limited improvement in ORR ( 25 ). Most recently, the NUVOLA trial is recruiting patients to evaluate neoadjuvant olaparib and weekly TC (carboplatin plus paclitaxel) in unresectable OC ( 26 ).…”

Section: Discussionmentioning

confidence: 99%

Effectiveness and Safety of Niraparib as Neoadjuvant Therapy in Advanced Ovarian Cancer With Homologous Recombination Deficiency (NANT): Study Protocol for a Prospective, Multicenter, Exploratory, Phase 2, Single-Arm Study

Zhou

Liu

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

BackgroundOvarian cancer (OC) is a heterogeneous gynecological malignancy with a poor prognosis as the majority of patients are diagnosed at an advanced stage. Neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) is recommended for patients who cannot achieve optimal cytoreduction or cannot endure primary debulking surgery (PDS). As there is an increased risk of chemoresistance for platinum-based NACT, it is important to investigate an alternative option. A Poly (ADP-ribose) polymerase inhibitor (PARPi), niraparib, has shown high anti-tumor activity, especially in homologous recombination deficiency (HRD) positive patients with OC. Thus, niraparib as a neoadjuvant treatment agent may help improve surgery accessibility and create survival benefits.MethodsThis multicenter, prospective, single-arm, open-label, phase II study plans to recruit 53 patients (aged 18-75 years) with newly diagnosed HRD positive, unresectable (Fagotti score ≥ 8 or upper abdominal computed tomography [CT] score ≥ 3) International Federation of Gynecology and Obstetrics (FIGO) stage III-IV OC. The HRD status was detected by next-generation sequencing and HRD positive patients will be counseled for study participation. Enrolled patients will receive niraparib capsules QD (200mg or 300mg per day) for two cycles (4 weeks/cycle). After neoadjuvant niraparib treatment, patients exhibiting complete response (CR), partial response (PR), or stable disease (SD) will undergo tumor reduction surgery and subsequent standard carboplatin/paclitaxel-based chemotherapy. The primary objectives include the objective response rate (ORR) and R0 resection rate. The rate of treatment interruption/termination and progression-free survival (PFS) will be secondary objectives. The study uses Simon’s optimal two-stage design (24 and 21 patients for the first and second stage respectively). The data manager will record all adverse events (AEs).DiscussionThis is the first prospective study to evaluate the effectiveness and safety of niraparib in neoadjuvant treatment for advanced OC. The result of this study will provide a solid base for further expanding the clinical applications of the PAPRi and exploring more therapeutic possibilities for patients with HRD positive advanced OC. Clinical Trial Registration: https://clinicaltrials.gov/, identifier NCT04507841.

show abstract

Section: Discussionmentioning

confidence: 99%

Effectiveness and Safety of Niraparib as Neoadjuvant Therapy in Advanced Ovarian Cancer With Homologous Recombination Deficiency (NANT): Study Protocol for a Prospective, Multicenter, Exploratory, Phase 2, Single-Arm Study

Zhou

Liu

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Recently an expert panel from India has recommended the use of 7.5 mg/kg in ovarian cancers considering the practicality in clinical use. 35…”

Section: Maintenance Therapymentioning

confidence: 99%

Therapy for Recurrent High-Grade Epithelial Ovarian Cancer—The Current Status and Future Trends

Harindran

Sadanandan

Sreedath

et al. 2022

Indian J Med Paediatr Oncol

View full text Add to dashboard Cite

Ovarian malignancy is the seventh most frequently diagnosed cancer among women. The most common type is epithelial ovarian cancer. Several subtypes with distinct biological and molecular properties exist, and there is inconsistency in availability of and access to different modalities of treatment. The standard first-line management is combining surgery and platinum-based chemotherapy. Most of them are diagnosed at an advanced stage due to which they have poor outcomes. The existing screening tests have a low predictive value. Even with the best available upfront treatment, high rates of recurrences are observed. As a result, there have been major advances in the treatment of recurrences with the development of anti-angiogenic agents and PARP inhibitors. It has led to the improvement in survival and quality of life among the relapsed epithelial ovarian cancers. This review is focused on the management of recurrent epithelial ovarian cancers and future directions based on current evidence. The application of a personalized and structured approach will meaningfully bring changes in the paradigm of care in these groups of patients.

show abstract

Use of Bevacizumab in Advanced Ovarian Cancer: Consensus from an Expert Panel Oncologists

Cited by 2 publications

References 22 publications

Effectiveness and Safety of Niraparib as Neoadjuvant Therapy in Advanced Ovarian Cancer With Homologous Recombination Deficiency (NANT): Study Protocol for a Prospective, Multicenter, Exploratory, Phase 2, Single-Arm Study

Effectiveness and Safety of Niraparib as Neoadjuvant Therapy in Advanced Ovarian Cancer With Homologous Recombination Deficiency (NANT): Study Protocol for a Prospective, Multicenter, Exploratory, Phase 2, Single-Arm Study

Therapy for Recurrent High-Grade Epithelial Ovarian Cancer—The Current Status and Future Trends

Contact Info

Product

Resources

About